- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01465880
Smoking Research Study
A Single-centre, Dose Titration Study in Healthy Volunteers (Smokers and Non-smokers) to Evaluate the Capacity of 2-cyanoethylmercapturic Acid (CEMA) to Detect Low Level of Cigarette Smoking Exposure
Study Overview
Detailed Description
This study will be performed in two parts. The first part, Part A, is a dose titration study in healthy smokers with incremental cigarette consumption performed in confinement. The second part, Part B, is an observational study on healthy non-smokers in an ambulatory setting
PART A (smokers only)
A screening visit will be conducted within 4 weeks prior to admission to the investigational site. The 8-day confinement period consists of the admission day (Day1), 1 day ad-libitum smoking (Day0), 3 days of smoking abstinence (Day1-3), 2-day exposure period smoking 2 and 4 cigarettes (Day4-5), and the day of discharge (Day6) followed by a 7-day safety follow-up period. Urine collection will be performed for each subject from Day0 to Day5 in 4 intervals.
PART B (non-smokers)
Screening visit will be conducted within 4 weeks prior to the ambulatory Visit 1 (collection of 24-hour urine and spot urine) to the investigational site. The minimum interval between the screening and Visit 1 is of 7 days.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
South Wales
-
Merthyr Tydfil, South Wales, United Kingdom, CF48 4DR
- Simbec Research Ltd
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Common criteria to smokers and non-smokers
- Subject is able to understand the information provided in the Subject Information sheet and Informed Consent Form (ICF)
- Subject has signed the ICF
- Subject of Caucasian origin
- Aged from 23 to 55 years
Having acceptable health conditions as judged by the Investigator at the screening visit based on clinical laboratory parameters (clinical biochemistry, urine analysis and standard haematology), spirometry, serology, urine drug screen, vital signs, physical examination, ECG, and medical history
Specific to smokers
- Current smoker based on self-reporting who smoke 5 to 15 commercially available non-mentholated conventional cigarettes (no brand restrictions) with a maximum tar yield of 10 mg (ISO method, as labelled on the cigarette package) smoking at least for the last 3 consecutive years. The smoking status will be verified at screening based on a urinary cotinine test (cotinine ≥200ng/ml)
Subject is willing to smoke according to the smoking regimen of the study
Specific to non-smokers
- Non-smoker based on self-reporting who have not used any tobacco or nicotine containing product including commercially available cigarettes, hand-rolled cigarettes, cigars, pipes, snuff, electronic cigarettes, similar devices, and nicotine replacement therapy within the last 12 months. The non-smoking status of the subject will be verified at screening based on a urinary cotinine test (cotinine <200ng/ml)
Exclusion Criteria:
Common criteria to smokers and non-smokers
- As per judgement of the Investigator, any subject who cannot participate in the study for any reason (e.g., medical, psychiatric and/or social reason)
- Any clinically relevant gastrointestinal, renal, hepatic, neurological, haematological, endocrine, oncological, urological, immunological and cardiovascular diseases or any other condition including clinically significant abnormal laboratory parameters that, in the opinion of the Investigator, could jeopardise the safety of the subject or impact the validity of the study results
- Lung cancer, upper respiratory tract cancers, chronic respiratory diseases or any other clinically significant pulmonary diseases according to the judgement of the Investigator
- Any medical conditions requiring smoking cessation (e.g., recent acute cardiovascular event, diabetes mellitus, Chronic Obstructive Pulmonary disease)
- Subject with body mass index < 18.5 or ≥ 30 kg/m2
- As per judgement of the Investigator, medical conditions which require or will require in the course of the study a medical intervention (e.g., start of treatment, surgery, hospitalisation) which may interfere with the study participation and/or study results
- Donation or receipt of whole blood or blood products within 3 months prior to the screening visit
- Participation in any clinical studies within 3 months before the screening visit
- Current or former employee of the tobacco industry, or of their first-degree relatives (parent, sibling, child)
- Employee of the investigational site or any other parties involved in the study or of their first-degree relatives (parent, sibling, child)
- Enrolled in the same study at a different time (i.e., each subject can be in the study population only once)
- Subject who is legally incompetent, physically or mentality incapable of giving consent (e.g., emergency situation, under guardianship, subject in a social or sanitary establishment, prisoners or subject who are involuntarily incarcerated)
- Positive alcohol test and/or history of alcohol abuse that could interfere with subject's participation in study
- Positive urine drug tests (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine and opiates)
Positive serology test (HbsAg, HCV, HIV)
Specific to smokers
Subject who has used any nicotine-containing products other than commercially available cigarettes (either a tobacco-based product or nicotine-replacement therapy) as well as electronic cigarettes and similar devices within 1 month prior to the screening visit
Additionally, women of childbearing potential must be excluded if:
- Subject is pregnant (does not have negative pregnancy tests at screening and at admission) or breastfeeding
- Subject does not agree to use an acceptable method of effective contraception: intrauterine device, intrauterine system, established use of oral/injectable/implantable/transdermal hormonal methods, barrier methods of contraception (condoms, occlusive caps) with spermicidal foam/gel/film/suppository, vasectomised partner or true abstinence (periodic abstinence and withdrawal are not effective methods) from screening until the end of the safety follow-up period
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Part B. Healthy Caucasian adult non-smokers
Non-smokers
|
|
Experimental: Part A.Healthy Caucasian adult smokers
No product will be investigated in this study.
Smokers will smoke their own conventional cigarettes only.
|
Smoking abstinence, smoking 2 and 4 cigarettes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Levels of CEMA, a biomarker of exposure to acrylonitrile, in 24-hour urine of smokers smoking 2 or 4 conventional cigarettes
Time Frame: After smoking 2 or 4 conventional cigarettes, within 24 hours
|
To demonstrate that CEMA, used as a urinary biomarker, can identify subjects who have smoked 4 or less conventional cigarettes
|
After smoking 2 or 4 conventional cigarettes, within 24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Levels of CEMA in 24-hour urine, carboxyhaemoglobin (COHb) in blood and carbon monoxide in exhaled breath of smokers smoking 2 or 4 conventional cigarettes
Time Frame: After smoking 2 or 4 conventional cigarettes, within 24 hours
|
To evaluate the ability of CEMA to detect conventional cigarette use in comparison to COHb and exhaled carbon monoxide
|
After smoking 2 or 4 conventional cigarettes, within 24 hours
|
Levels of CEMA, a biomarker of exposure to acrylonitrile, in 24-hour and spot urine of non-smokers
Time Frame: 24 hours
|
To evaluate the correlation between the levels of CEMA in 24-hour urine and in spot urine in non-smokers
|
24 hours
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- PIPA_CEMA_01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking
-
University of Southern CaliforniaAmerican Cancer Society, Inc.CompletedSmoking | Smoking Cessation | Smoking, Cigarette | Smoking Behaviors | Cessation, SmokingUnited States
-
University of VirginiaRecruitingSmoking | Smoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking, Cigarette | Quitting SmokingUnited States
-
Columbia UniversityNational Cancer Institute (NCI)RecruitingSmoking | Smoking Cessation | Smoking Reduction | Smoking BehaviorsUnited States
-
National Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Cigarette Smoking | Tobacco, SmokingUnited States
-
University GhentRecruitingSmoking | Smoking Tobacco | Smoking Prevention | Smoking CigaretteBelgium
-
Medical University of South CarolinaCompletedSmoking | Smoking Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Maastricht University Medical CenterThe Investigative Desk; SEO Amsterdam Economics; IVO Research InstituteEnrolling by invitationSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking BehaviorsNetherlands
-
Jennifer Marler, MDCompletedSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking BehaviorsUnited States
-
Medical University of South CarolinaRecruitingSmoking | Smoking Cessation | Tobacco Smoking | Cigarette SmokingUnited States
-
Ghana Health ServicesKwame Nkrumah University of Science and TechnologyNot yet recruitingSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking Behaviors
Clinical Trials on Part A
-
AstraZenecaParexelRecruiting
-
Verona Pharma plcIqvia Pty LtdCompleted
-
Eli Lilly and CompanyCompleted
-
AstraZenecaCompletedGonococcal (GC) InfectionUnited States
-
GLWL Research Inc.TerminatedDiabetes Mellitus, Type 2United States
-
GlaxoSmithKlineTerminatedMultiple Sclerosis, Relapsing-RemittingUnited Kingdom
-
Verona Pharma plcIqvia Pty LtdCompletedPulmonary Disease, Chronic ObstructiveUnited States
-
Emory UniversityTerminatedSickle Cell DiseaseUnited States
-
Mereo BioPharmaNovartisTerminatedAcute Kidney InjuryTaiwan, United States, Israel